Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

685 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma.
Ryl T, Afanasyeva E, Hartmann T, Schwermer M, Schneider M, Schröder C, Wagemanns M, Bister A, Kanber D, Steenpass L, Schramm K, Jones B, Jones DTW, Biewald E, Astrahantseff K, Hanenberg H, Rahmann S, Lohmann DR, Schramm A, Ketteler P. Ryl T, et al. Among authors: schramm a, schramm k. Commun Biol. 2024 Jul 30;7(1):919. doi: 10.1038/s42003-024-06596-6. Commun Biol. 2024. PMID: 39079981 Free PMC article.
Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.
Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt Vv, Sieverts H, Kuhfittig-Kulle S, Pfeiffer P, Versteeg R, Eggert A. Schramm A, et al. Cancer Lett. 2005 Oct 18;228(1-2):143-53. doi: 10.1016/j.canlet.2005.02.051. Cancer Lett. 2005. PMID: 15921851 Review.
MYCN regulates oncogenic MicroRNAs in neuroblastoma.
Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B. Schulte JH, et al. Among authors: schramm a. Int J Cancer. 2008 Feb 1;122(3):699-704. doi: 10.1002/ijc.23153. Int J Cancer. 2008. PMID: 17943719
Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A, Köster J, Marschall T, Martin M, Schwermer M, Fielitz K, Büchel G, Barann M, Esser D, Rosenstiel P, Rahmann S, Eggert A, Schulte JH. Schramm A, et al. Int J Cancer. 2013 Feb 1;132(3):E106-15. doi: 10.1002/ijc.27787. Epub 2012 Sep 26. Int J Cancer. 2013. PMID: 22907398
Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.
Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Köster J, Vandesompele J, Vermeulen J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH. Schramm A, et al. Br J Cancer. 2012 Oct 9;107(8):1409-17. doi: 10.1038/bjc.2012.391. Br J Cancer. 2012. PMID: 23047593 Free PMC article.
Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A. Schulte JH, et al. Among authors: schramm a. Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Klin Padiatr. 2013. PMID: 24166094 Review.
685 results